查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年胸腺癌全球市场
市场调查报告书
商品编码
1272774

2023-2030 年胸腺癌全球市场

Global Thymus Cancer Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

胸腺癌的全球市场预计将在 2022 年达到 4.614 亿美元，预计到 2030 年将达到 7.025 亿美元。 胸腺癌市场预计在预测期内（2023-2030 年）的复合年增长率为 5.5%。 主要参与者正在采取合作伙伴关係、合併、收购、产品批准和区域扩张等战略，以在胸腺癌市场中脱颖而出，成为强大的竞争对手。

例如，2023 年 1 月 17 日，默克公司的抗 PD-1 药物 KEYTRUDA 被手术用于患有 IB 期（T2a 4 cm）、II 期或 IIIA 期非小细胞肺癌的成年患者。美国食品和药物管理局 (FDA) 将其作为单药作为切除和铂类化疗 (NSCLC) 后的辅助治疗。

胸腺癌是一种恶性（癌）细胞在胸腺中形成的疾病。 胸腺瘤、胸腺癌和胸腺神经内分泌肿瘤 (TNET)，也称为胸腺上皮肿瘤 (TET)，是一种在胸腺排列的细胞中形成的罕见癌症。 市场的逐步发展、胸腺癌病例数量的增加以及研究活动的增加是预计在预测期内推动全球胸腺癌市场增长的一些因素。

市场动态

胸腺癌病例增加推动胸腺癌市场增长

胸腺癌患病率的增加预计将推动市场增长。 例如，根据英国癌症研究中心的数据，胸腺癌很罕见。 英国每年约有 345 人被诊断出患有胸腺癌。 这包括胸腺瘤和胸腺癌。

但是，确切的数字是未知的，并且可能高于计算机断层扫描可以检测到的估计数字。 胸腺瘤和胸腺癌通常发生在 40 至 60 岁的人群中，但它们几乎可以发生在任何年龄段。 因此，老年人口的增加可能会导致胸腺癌的流行。

研究活动的增加为市场带来了增长机会

有几种方法可以开发胸腺癌的新疗法，这将为未来几年的胸腺癌市场提供有利可图的增长机会。 例如，研究人员正在探索使用免疫疗法来利用免疫系统的力量来靶向和摧毁癌细胞。 正在考虑其他方法，例如专注于参与胸腺癌发生和进展的特定分子途径的靶向治疗。

COVID-19 影响分析

对 COVID-19 的分析包括 COVID 之前、COVID 和 COVID 之后的情景、价格动态（与 COVID 之前的情景相比，大流行期间和之后的价格变化）、供需范围（需求和供应的变化由于贸易限制、封锁和后续问题）；行动）也有解释。

俄乌衝突分析

由于该地区缺乏主要市场参与者且该疾病的总体患病率较低，预计俄乌衝突对全球胸腺癌市场的影响可以忽略不计。 然而，这场战争预计对全球胸腺癌市场的影响最小，削弱了在该地区进行的研究活动。

全球经济衰退影响分析

医疗保健行业并非完全不受衰退影响。 但这个行业，就其本质而言，比其他行业应对得更好。 经济衰退导致研究投资下降，这对过去几年的市场增长产生了负面影响。

人工智能影响分析

AI在不同癌症中的应用不成比例，对纵隔肿瘤的关注不够，未来发展空间和潜力较大。 例如，汕头市中心医院放射科的研究人员得出结论，基于机器学习的 CT 图像在预测调查的不同组织学分类以及浸润水平方面具有重要价值。 因此，人工智能有望在未来几年对全球胸腺癌市场产生积极影响。

了解有关此报告的更多信息 - 索取样本

内容

第一章调查方法及范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按癌症类型分类的摘要
  • 按治疗方法
  • 最终用户
  • 区域摘要

第四章市场动态

  • 影响因素
    • 司机
      • 积极发展新兴市场
      • 启动研究活动
    • 约束因素
      • 对疾病了解不足
    • 机会
      • 增加筹款和投资
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第七章俄乌战争分析

第八章全球经济衰退分析

第9章人工智能的影响分析

第 10 章癌症类型

  • 胸腺瘤
    • 类型A
    • AB型
    • 类型 B1
    • B2型
    • B3型
  • 胸腺癌
  • 胸腺神经内分泌肿瘤 (TNET)
  • 其他

第11章治疗

  • 手术治疗
  • 化疗
    • 多柔比星（阿霉素）
    • 顺铂 (Platinol)
    • 卡铂（准铂）
    • 其他
  • 放射治疗
  • 其他

第 12 章最终用户

  • 医院
  • 癌症治疗和研究中心
  • 门诊手术中心
  • 学术和研究机构

第13章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第14章竞争格局

  • 竞争场景
  • 市场份额分析
  • 併购分析

第十五章公司简介

  • 默克公司
    • 公司概况
    • 产品组合和说明
    • 财务摘要
    • 主要发展状况
  • Viatris Inc.
  • F. Hoffmann-La Roche Ltd
  • Elekta AB
  • Asensus Surgical US, Inc.
  • Pfizer Inc.
  • Getwell Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Intuitive Surgical
  • Varian Medical Systems, Inc.（Siemens Healthineers AG）

第16章 附录

简介目录
Product Code: PH2037

Market Overview

The global thymus cancer market reached US$ 461.4 million in 2022 and is projected to witness to reach up to US$ 702.5 million by 2030. The thymus cancer market is expected to exhibit a CAGR of 5.5% during the forecast period (2023-2030). The key players are adopting strategies such as partnerships, mergers, acquisitions, product approvals, and regional expansion to stand out as strong competitors in the thymus cancer market.

For instance, on January 17, 2023, for adult patients with stage IB (T2a 4 cm), stage II, or stage IIIA non-small cell lung cancer, Merck's anti-PD-1 medication, KEYTRUDA, was approved by the U.S. Food and Drug Administration (FDA) as a single agent for adjuvant treatment after surgical resection and platinum-based chemotherapy (NSCLC).

Thymus cancer is a disease in which malignant (cancer) cells form in the thymus. Thymoma, Thymic Carcinoma, and Thymic Neuroendocrine Tumor (TNET) also called thymic epithelial tumors (TETs), are types of rare cancers that can form in the cells covering the thymus's outside surface. The increasing market developments, growing cases of thymus cancer, and increasing research activities are some of the factors that are expected to drive the global thymus cancer market growth over the forecast period.

Market Dynamics

The increasing cases of thymus cancer are driving the thymus cancer market growth

The increasing prevalence of thymus cancer is expected to boost the market growth. For instance, according to Cancer Research UK, thymus gland cancer is rare. In the U.K., around 345 people are diagnosed with thymus cancer each year. This includes thymoma and thymic carcinoma.

However, the exact number is not known and may be higher than the estimated number that can be detected using computed tomography scans. Thymoma and thymic carcinoma usually occurs in people between the ages of 40 and 60 but can occur at almost any age. Thus, the rising older population is likely to contribute to thymus cancer prevalence.

The growing research activities provide the market with growth opportunities

There are several approaches that could be pursued to develop new treatments for thymus cancer presenting the thymus cancer market with lucrative growth opportunities in the forthcoming years. For example, researchers are exploring the use of immunotherapies, which harness the power of the immune system to target and destroy cancer cells. Other potential approaches include targeted therapies that focus on specific molecular pathways involved in the development and progression of thymus cancer.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war is estimated to have nearly negligible impact on the global thymus cancer market, owing to the absence of key market players in this region and the overall low prevalence of the condition. Still, the war has slowed the research activities carried out in this region, which is expected to have the slightest impact on the global thymus cancer market.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. The recession has led to a decrease in research investments which has negatively impacted the market growth in the past few years.

Artificial Intelligence Impact Analysis

The application of AI in different cancers is disproportionate, and enough attention has not been paid to mediastinal tumors, showing a huge gap and potential for future development. For instance, the researchers from the Department of Radiology, Shantou Central Hospital concluded that the machine learning-based CT image had significant values in the prediction of different histological classifications and even invasion levels from their investigation. Thus, artificial intelligence is estimated to positively impact the global thymus cancer market in the upcoming years.

For more details on this report - Request for Sample

Segment Analysis

The global thymus cancer market is segmented based on cancer type, treatment, end users, and region.

The surgical treatment segment is estimated to hold 39.3% of the total market by 2030

Surgical removal of the tumor is the primary form of treatment for thymus cancer. An incision is made in the center of the chest and the sternum (chest bone) is split, allowing the surgeon full access to the thymus gland. Depending on the extent of cancer, the tumor is removed and the entire thymus gland is removed (a procedure called a thymectomy), and/or parts of nearby organs where the tumor has spread. Moreover, the rising clinical research activities are boosting the surgery treatment segment growth in the forecast period.

For instance, in 2022, according to ClinicalTrials.com., Shanghai Zhongshan Hospital completed an interventional study comparing the safety and perioperative outcomes of the subxiphoid approach versus lateral intercostal approach thoracoscopic thymectomy for Masaoka-Koga I-II Thymoma.

Geographical Analysis

Europe is estimated to hold the second-largest share of the global thymus cancer market during the forecast period

The increasing initiatives and funding in the fight against thymus cancer in this region are boosting the European thymus cancer market growth and are estimated to hold around 26.2% of the global thymus cancer market by 2030. For instance, ThymicUK, a registered charity established by patients with thymic cancers, their carers, and families and friends, raised slightly more than £10,000 from fundraisers and grants to support those impacted by rare thymic cancers.

Competitive Landscape

The major global players in the market include Merck & Co., Inc., Viatris Inc., F. Hoffmann-La Roche Ltd, Elekta AB, Asensus Surgical US, Inc., Pfizer Inc., Getwell Pharmaceuticals, Bristol-Myers Squibb Company, Intuitive Surgical and Varian Medical Systems, Inc. (Siemens Healthineers AG) among others.

Why Purchase the Report?

  • To visualize the global thymus cancer market segmentation based on product, application, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of thymus cancer market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global thymus cancer market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Cancer Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased Market Developments
      • 4.1.1.2. Increasing Research Activities
    • 4.1.2. Restraints
      • 4.1.2.1. Limited Disease Understanding
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing Fundings and Investments
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Cancer Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.1.2. Market Attractiveness Index, By Cancer Type
  • 10.2. Thymoma
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 10.2.3. Type A
    • 10.2.4. Type AB
    • 10.2.5. Type B1
    • 10.2.6. Type B2
    • 10.2.7. Type B3
  • 10.3. Thymic carcinoma
  • 10.4. Thymic Neuroendocrine Tumor (TNET)
  • 10.5. Others

11. By Treatment

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 11.1.2. Market Attractiveness Index, By Treatment
  • 11.2. Surgery*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Chemotherapy
    • 11.3.1. Doxorubicin (Adriamycin)
    • 11.3.2. Cisplatin (Platinol)
    • 11.3.3. Carboplatin (Paraplatin)
    • 11.3.4. Others
  • 11.4. Radiation therapy
  • 11.5. Others

12. By End User

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.1.2. Market Attractiveness Index, By End User
  • 12.2. Hospitals*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Cancer Care and Research Centers
  • 12.4. Ambulatory Surgery Centers
  • 12.5. Academics and Research Institutes

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.6.1. The U.S.
      • 13.2.6.2. Canada
      • 13.2.6.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.6.1. Germany
      • 13.3.6.2. The U.K.
      • 13.3.6.3. France
      • 13.3.6.4. Italy
      • 13.3.6.5. Spain
      • 13.3.6.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.6.1. Brazil
      • 13.4.6.2. Argentina
      • 13.4.6.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.6.1. China
      • 13.5.6.2. India
      • 13.5.6.3. Japan
      • 13.5.6.4. Australia
      • 13.5.6.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Merck & Co., Inc.*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Viatris Inc.
  • 15.3. F. Hoffmann-La Roche Ltd
  • 15.4. Elekta AB
  • 15.5. Asensus Surgical US, Inc.
  • 15.6. Pfizer Inc.
  • 15.7. Getwell Pharmaceuticals
  • 15.8. Bristol-Myers Squibb Company
  • 15.9. Intuitive Surgical
  • 15.10. Varian Medical Systems, Inc. (Siemens Healthineers AG)

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us